

Amendments to the Claims

117 (previously presented): A composition for use in reverse transcription of a nucleic acid molecule, said composition comprising two or more viral reverse transcriptases.

118 (previously presented): The composition of claim 117, wherein said reverse transcriptases are retroviral reverse transcriptases.

119 (currently amended): The composition of claim 117, wherein said reverse transcriptases are selected from the group consisting of Moloney Murine Leukemia Virus (M-MLV), ~~Avian Sarcoma-Leukosis Virus (ASLV)~~; Rous Sarcoma Virus (RSV), Avian Myeloblastosis Virus (AMV), Rous Associated Virus (RAV), Myeloblastosis Associated Virus (MAV), and Human Immunodeficiency Virus (HIV) reverse transcriptases.

120 (currently amended): The composition of claim 117, wherein said reverse transcriptases comprise an ~~ASLV~~ α subunit, an ~~ASLV~~ β subunit, an ~~ASLV~~ α β 4 subunit, or a combination thereof.

121 (previously presented): The composition of claim 117, wherein the transcription pause site of each of said reverse transcriptases is different from that of each of the other reverse transcriptase in said composition.

122 (canceled)

123 (currently amended): The composition of claim 117, wherein at least one of said reverse transcriptases has substantially reduced RNase H activity compared to the corresponding wild-type reverse transcriptase.

124 (previously presented): The composition of claim 117, wherein at least one of said reverse transcriptases lacks RNase H activity.

125 (currently amended): The composition of any of claims [[122]] 123-124, wherein at least one of said reverse transcriptase is selected from the group consisting of MMLV, ~~ASLV~~, RSV, AMV, RAV, MAV, and HIV reverse transcriptases.

126 (currently amended): The composition of any one of claims [[122]] 123-124, wherein at least one of said reverse transcriptase comprises an ~~ASLV~~ α subunit, ~~an ASLV~~ β subunit, ~~an ASLV~~ β p4 subunit, or a combination thereof.

127 (canceled)

128 (currently amended): The composition of claim 117, wherein at least one of said reverse transcriptases is a mutant or fragment reverse transcriptase that has substantially reduced RNase H activity compared to the corresponding wild-type reverse transcriptase.

129 (previously presented): The composition of claim 117, wherein at least one of said reverse transcriptases is a mutant or fragment reverse transcriptase that lacks RNase H activity.

130 (previously presented): The composition of claim 117, wherein said reverse transcriptases are present in said composition at working concentrations.

131 (previously presented): A kit for use in reverse transcription of a nucleic acid molecule, said kit comprising two or more viral reverse transcriptases.

132 (previously presented): The kit of claim 131, wherein said reverse transcriptases are retroviral reverse transcriptases.

133 (currently amended): The kit of claim 131, wherein said reverse transcriptases are selected from the group consisting of MMLV, ~~ASLV~~, RSV, AMV, RAV, MAV, and HIV reverse transcriptases.

134 (currently amended): The kit of claim 131, wherein said reverse transcriptases comprise an ~~ASLV~~ α subunit, an ~~ASLV~~ β subunit, an ~~ASLV~~ β p4 subunit, or a combination thereof.

135 (previously presented): The kit of claim 131, wherein the transcription pause site of each of said reverse transcriptases is different from that of each of the other reverse transcriptase in said composition.

136 (canceled)

137 (currently amended): The kit of claim 131, wherein at least one of said reverse transcriptases has substantially reduced RNase H activity compared to the corresponding wild-type reverse transcriptase.

138 (previously presented): The kit of claim 131, wherein at least one of said reverse transcriptases lacks RNase H activity.

139 (currently amended): The kit of any one of claims [[136]] 137-138, wherein at least one of said reverse transcriptases is selected from the group consisting of MMLV, ~~ASLV~~, RSV, AMV, RAV, MAV, and HIV reverse transcriptases.

140 (currently amended): The kit of any one of claims [[136]] 137-138, wherein at least one of said reverse transcriptases comprises an ~~ASLV~~ α subunit, an ~~ASLV~~ β subunit, an ~~ASLV~~ β p4 subunit, or a combination thereof.

141 (canceled)

142 (currently amended): The kit of claim 131, wherein at least one of said reverse transcriptases is a mutant or fragment reverse transcriptase that has substantially reduced RNase H activity compared to the corresponding wild-type reverse transcriptase.

143 (previously presented): The kit of claim 131, wherein at least one of said reverse transcriptases is a mutant or fragment reverse transcriptase that lacks RNase H activity.

144 (previously presented): The kit of claim 131, wherein said reverse transcriptases are present in said kit at working concentrations.

145 (previously presented): The kit of claim 131, said kit further comprising one or more components selected from the group consisting of one or more nucleotides, one or more DNA polymerases, a suitable buffer, one or more primers and one or more terminating agents.

146 (previously presented): The kit of claim 145, wherein said terminating agent is a dideoxynucleotide.

147 (previously presented): The kit of claim 145, wherein two or more of the components of said kit are present as a mixture or are present as separate components.

148-213 (canceled)